Episode 3: Cracking the Code of Small Renal Masses: Sestamibi, MRI, & Targeted RCC Detection

In this episode of Beyond the Biopsy, Dr. Nitin Yerram sits down with Dr. Gopal Gupta to discuss the evolving evaluation and management of small renal masses. They explore the growing incidence of incidentally detected kidney tumors and the longstanding challenge of distinguishing benign lesions from malignant ones. Dr. Gupta explains the strengths and limitations of traditional imaging, surveillance, and renal mass biopsy, emphasizing the need for more accurate diagnostic tools that can help clinicians avoid unnecessary interventions. The discussion focuses on several emerging imaging technologies that may transform kidney cancer diagnosis. Dr. Gupta reviews the biologic rationale and clinical data behind sestamibi imaging, which can help identify benign oncocytomas, as well as the MRI-based Peak Early Enhancement Ratio (PEER) metric being studied to differentiate oncocytoma from chromophobe renal tumors. They also examine the promise of girentuximab, a novel molecular imaging agent designed to detect clear cell renal cell carcinoma, including findings from the ZIRCON trial.